Boehringer Ingelheim Survodutide (BI 456906, Dual GLP-1/Glucagon Receptor Agonist) Phase 2 MASH (Metabolic Dysfunction-Associated Steatohepatitis) Results Continue to Circulate Ahead of Phase 3 Readouts Expected in Late 2026: 83% of MASH Patients Achieved Histological Improvement at 48 Weeks, With Phase 3 Trials for Both MASH and Obesity Underway; Survodutide Positions Boehringer to Compete Against Novo Nordisk Semaglutide (Wegovy), Eli Lilly Tirzepatide (Zepbound/Mounjaro), and the Eventual Retatrutide Triple Agonist in the Broader Cardiometabolic Space
Boehringer Ingelheim's survodutide (BI 456906) Phase 2 MASH results continue to circulate through the pharma analyst community ahead of Phase 3 readouts expected in late 2026. Survodutide is a dual GLP-1 / glucagon receptor agonist administered by once-weekly subcutaneous injection. In the Phase 2 trial in patients with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH), 83% of survodutide-treated patients achieved histological improvement at 48 weeks (versus placebo comparator). Phase 3 trials for both MASH (LIVERAGE program) and obesity (SYNCHRONIZE program) are underway. Survodutide positions Boehringer Ingelheim to compete against Novo Nordisk semaglutide (Wegovy for obesity, Ozempic for type 2 diabetes) which has approximately 15% weight loss and Rezdiffra (resmetirion) FDA-approved March 2024 for MASH; Eli Lilly tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes) which has approximately 21% weight loss; and the eventual Eli Lilly retatrutide triple GLP-1/GIP/glucagon agonist (Phase 3 TRIUMPH program) which showed 28.3% weight loss in Phase 3 obesity readouts earlier in 2026. The dual-agonist glucagon mechanism differentiates survodutide from the pure GLP-1 and GLP-1/GIP incumbents by adding hepatic glucose output modulation and potential MASH-specific liver benefit.